Results of a study investigating orelabrutinib for first line treatment of CLL.
Home / Resource Library / Orelabrutinib versus chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial